Hieff Trans™ UltraLV Transfection Reagent (PEI) _ 40825ES

YeasenSku: 40825ES01

Size: 100 μL
Цена:
Цена продажи$95.00
Запас:
В наличии

This product is specifically developed for the large-scale production of lentiviral vectors (LV). It is an optimized, linearized polyethylenimine (Linear PEI).

Synthesized entirely through chemical processes, this product is free of animal-derived components and exhibits low cytotoxicity. It is provided as a sterile liquid solution and is fully compatible with both suspension and adherent HEK293 cell systems for LV packaging. Featuring high DNA loading capacity, a low transfection complex ratio, and high complex stability, it greatly facilitates large-scale LV production.

Features

Higher Viral Yield: Increases viral production by 2-3 fold.

Broader Applicability: Suitable for lentiviral (LV) vector preparation in both adherent and suspension cell systems.

Superior Compatibility: Delivers enhanced viral yields for both 4-plasmid and 5-plasmid packaging systems.

Specifications

Cat.No.

40825ES01 / 40825ES03 / 40825ES10 / 40825ES60

Size

100 μL / 1 mL / 10 mL / 100 mL

Components

Components No.

Name

40825ES01

40825ESO3

40825ES10

40825ES60

40825

Hieff Trans™ UltraLV Transfection Reagent

100 μL

1 mL

10 mL

100 mL

Figures

HEK293 (G2S) case study

Figure 1. Enhanced Lentiviral (LV) Yield Under identical experimental conditions (with only the transfection reagent varied), Yeasen reagent achieves a 2-fold increase in lentiviral titer compared to leading commercial alternatives.
Figure. Enhanced Lentiviral (LV) Yield
Under identical experimental conditions (with only the transfection reagent varied), Yeasen reagent achieves a 2-fold increase in lentiviral titer compared to leading commercial alternatives.
Figure 2. Simplified One-Step Transfection Workflow. The one-step protocol streamlines the process by directly adding the transfection reagent and plasmids into serum-free medium for co-incubation. This eliminates the separate dilution steps required in traditional two-step methods, significantly reducing pipetting and saving time.
Figure. Simplified One-Step Transfection Workflow.
The one-step protocol streamlines the process by directly adding the transfection reagent and plasmids into serum-free medium for co-incubation. This eliminates the separate dilution steps required in traditional two-step methods, significantly reducing pipetting and saving time.
Figure 3. High Stability of Transfection Complexes. The transfection complexes exhibit excellent stability, with viral yields remaining consistent whether incubated for 15 or 30 minutes. This demonstrates a broad operational window, providing greater procedural flexibility and accommodating varying laboratory workflows.
Figure. High Stability of Transfection Complexes.
The transfection complexes exhibit excellent stability, with viral yields remaining consistent whether incubated for 15 or 30 minutes. This demonstrates a broad operational window, providing greater procedural flexibility and accommodating varying laboratory workflows.
Figure. Minimal Cytotoxicity at High Reagent Ratios. 
Figure. Minimal Cytotoxicity at High Reagent Ratios.
Increasing the transfection reagent volume does not compromise cell health. At 48 hours post-transfection, cell viability remains stable at both 1:2 and 1:3 plasmid-to-reagent ratios, confirming the reagent's exceptionally low toxicity.
Figure Consistent performance across different batches

Storage

This product should be stored at 2~ 8 ℃ for 2 years.

FAQ

Citations

Documents

Applications

Вам также может понравиться

Расследование

Часто задаваемые вопросы

Продукт предназначен только для исследовательских целей и не предназначен для терапевтического или диагностического использования на людях или животных. Продукты и содержимое защищены патентами, товарными знаками и авторскими правами, принадлежащими Yeasen Biotechnology. Символы товарных знаков указывают на страну происхождения, а не обязательно на регистрацию во всех регионах.

Для некоторых приложений могут потребоваться дополнительные права интеллектуальной собственности третьих лиц.

Йесен привержен этической науке, полагая, что наши исследования должны затрагивать важнейшие вопросы, обеспечивая при этом безопасность и соблюдение этических стандартов.